Hao Lu

Hao Lu is an experienced biochemist with a robust background in preclinical research, specializing in immune-oncology, immunology, and oncology. Currently serving as Executive Director at Nurix Therapeutics since July 2021, Hao Lu previously held senior leadership roles at EMD Serono, Inc., overseeing teams focused on molecular pharmacology. Past positions at Bristol-Myers Squibb involved significant contributions in enzyme kinetics and assay development, while earlier academic roles included research on novel antibacterial agents at Stony Brook University and synthetic chemistry at The Chinese University of Hong Kong. Hao Lu holds a Doctorate in Biochemistry and Chemical Biology from Stony Brook University and a Bachelor's degree in Chemistry from The Chinese University of Hong Kong.